Affinity Technologies has appointed J. Michael Edwards as Chief Financial Officer. Takeaway Points bioAffinity Technologies ...

Affinity Technologies today announced it appointed J. Michael Edwards as chief financial officer in September.

Affinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at ...

More doctors are ordering bioAffinity Technologies' CyPath Lung test and sales are skyrocketing. A long-term military health ...

CyPath Lung is a laboratory-developed assay that uses self-collected sputum samples treated with a fluorescent compound that preferentially binds to cancer cells and cancer-related cells, San ...

SAN ANTONIO, Texas, August 14, 2024--bioAffinity Technologies reports financial results and operational highlights for the quarter ended June 30, 2024. SAN ANTONIO, August 05, 2024--bioAffinity ...

SAN ANTONIO, TX – bioAffinity Technologies, Inc. (NASDAQ:BIAF), a commercial physical and biological research services company, announced today that its shareholders have approved the issuance of ...

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today raised its full-year forecast ...

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that J. Michael ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Edwards will report directly to bioAffinity Technologies President and CEO Maria Zannes. "We are delighted to welcome Michael ...